Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reinhard Marks

Showing results (21-30 of 75) with videos related to

Pageof 8
Sort By:
The New England Journal of Medicine|April 11, 2019
Treatment of Progressive Multifocal Leukoencephalopathy with PembrolizumabSebastian Rauer, Reinhard Marks, Horst Urbach, et al.
Annals of Hematology|March 23, 2021
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCTHenning Schäfer, Jacqueline Blümel-Lehmann, Gabriele Ihorst, et al.
Blood|May 3, 2008
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignanciesReinhard Marks, Karin Potthoff, Joachim Hahn, et al.
European Journal of Haematology|October 10, 2024
Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL PatientsTim Strüßmann, Philipp Hermes, Gabriele Ihorst, et al.
Annals of Hematology|April 17, 2026
Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapyTino Vollmer, Tim Strüßmann, Franziska Glatzki, et al.
Journal of Neurology|July 1, 2021
Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and/or hematologic malignancy: a case series of five patientsTimo Volk, Klaus Warnatz, Reinhard Marks, et al.
Annals of Hematology|August 1, 2012
NT-pro-BNP: not the prognostic all-rounder in elderly patients undergoing allogeneic stem cell transplantationPeter S Haas, Gabriele Ihorst, Susanne Schnitzler, et al.
Annals of Hematology|November 17, 2022
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumabTim Strüßmann, Johannes Jung, Jürgen Heinz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphomaGerald Illerhaus, Reinhard Marks, Gabriele Ihorst, et al.
British Journal of Haematology|June 24, 2017
Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantationTim Strüßmann, Kristina Fritsch, Axel Baumgarten, et al.
Pageof 8

Showing results (21-30 of 75) with videos related to

Sort By:
Pageof 8
The New England Journal of Medicine|April 11, 2019
Treatment of Progressive Multifocal Leukoencephalopathy with PembrolizumabSebastian Rauer, Reinhard Marks, Horst Urbach, et al.
Annals of Hematology|March 23, 2021
A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCTHenning Schäfer, Jacqueline Blümel-Lehmann, Gabriele Ihorst, et al.
Blood|May 3, 2008
Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignanciesReinhard Marks, Karin Potthoff, Joachim Hahn, et al.
European Journal of Haematology|October 10, 2024
Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL PatientsTim Strüßmann, Philipp Hermes, Gabriele Ihorst, et al.
Annals of Hematology|April 17, 2026
Primary mediastinal B-cell lymphoma: upfront high-dose chemotherapy with autologous stem cell transplantation results in favorable long-term outcome and may spare radiotherapyTino Vollmer, Tim Strüßmann, Franziska Glatzki, et al.
Journal of Neurology|July 1, 2021
Pembrolizumab for treatment of progressive multifocal leukoencephalopathy in primary immunodeficiency and/or hematologic malignancy: a case series of five patientsTimo Volk, Klaus Warnatz, Reinhard Marks, et al.
Annals of Hematology|August 1, 2012
NT-pro-BNP: not the prognostic all-rounder in elderly patients undergoing allogeneic stem cell transplantationPeter S Haas, Gabriele Ihorst, Susanne Schnitzler, et al.
Annals of Hematology|November 17, 2022
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumabTim Strüßmann, Johannes Jung, Jürgen Heinz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphomaGerald Illerhaus, Reinhard Marks, Gabriele Ihorst, et al.
British Journal of Haematology|June 24, 2017
Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantationTim Strüßmann, Kristina Fritsch, Axel Baumgarten, et al.
Pageof 8